The global antiinfective medicine sales landscape reveals diverse trends across countries. Estonia leads with 15.4% of total sales in 2024, followed by the United Kingdom at 13.6%, and Iceland at 11.6%. Notable year-on-year (YoY) changes in 2023 include Luxembourg's remarkable 6.34% rise and South Korea’s significant -8.32% drop. While countries like Finland (-2.33%) and Switzerland (-3.86%) have seen declines, Estonia (+1.35%) and Norway (+1.22%) show positive trends. The Compound Annual Growth Rate (CAGR) over the past 5 years will likely reflect these varied performances across regions.
Overall, cautious optimism prevails for future trends. Key areas to watch include technological advancements in antiinfective treatments, emerging markets, and potential impacts of healthcare policy changes on market dynamics by country. These factors will substantially influence the growth trajectory and competitive landscape of global antiinfective medicine sales.
Top countries in Antiinfective Medicine Sales by Country
| # | 10 Countries | Percent of Total Sales | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Estonia | 15.4 | 2023 | +10% | +1.35% | View data |
| 2 | 2 United Kingdom | 13.6 | 2023 | +0.74% | +0.91% | View data |
| 3 | 3 Iceland | 11.6 | 2023 | 0% | +0.17% | View data |
| 4 | 4 Finland | 8.8 | 2023 | 0% | -2.33% | View data |
| 5 | 5 Norway | 8.5 | 2023 | -13.27% | +1.22% | View data |
| 6 | 6 Denmark | 7.8 | 2023 | -1.27% | -0.75% | View data |
| 7 | 7 Slovakia | 7.3 | 2023 | 0% | +0.28% | View data |
| 8 | 8 Switzerland | 6.9 | 2023 | 0% | -3.86% | View data |
| 9 | 9 South Korea | 6.8 | 2023 | -9.33% | -8.32% | View data |
| 10 | 10 Luxembourg | 6.8 | 2023 | +4.62% | +6.34% | View data |
